BF Biosciences Limited (PSX: BFBIO) posted a 16% increase in its net profit for the first quarter ended September 30, 2026 (1QFY27), reaching Rs184.88m compared to Rs159.52m in the same period last year.
Basic and diluted earnings per share (EPS) grew 15% to Rs2.09, up from Rs1.81 in 3MFY26. The bottom-line growth was supported by a 14% rise in net revenue and stronger gross margins.
| Description | 1QFY27 (Rs) | 1QFY26 (Rs) | Change % |
|---|---|---|---|
| Net Revenue | 2,783,886,116 | 2,432,294,309 | +14.5% |
| Gross Profit | 1,284,545,133 | 1,038,330,250 | +23.7% |
| Net Profit | 184,882,110 | 159,521,435 | +15.9% |
| Earnings Per Share (EPS) | 2.09 | 1.81 | +15.5% |
Read the full story on the original publisher’s website.
Open original article